Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.

This study found that patients with BPH who received finasteride before TURP experienced reduced intraoperative blood loss and improved quality of life one month after surgery compared to those who did not.

This review analyzes existing data and proposes a study design to evaluate the effectiveness of standardized PRP techniques for treating androgenetic alopecia, but reports no new clinical results.

In a study using an AGA mouse model, researchers observed that a novel topical gel combining hybrid extracellular vesicles, gold nanoparticles, and finasteride accelerated hair regrowth and improved hair quality more effectively than conventional minoxidil treatment, presenting a promising option with fewer side effects.

In this study, researchers presented a novel therapeutic approach for androgenetic alopecia combining AR-PROTAC degradation with regenerative strategies and evaluated the potential of GT20029 as a topical treatment, proposing a three-phase protocol and future research hypotheses.

This study found that plasma rich in growth factors showed promising results for increasing hair number and thickness in androgenic alopecia patients, with better outcomes after multiple injections.

This review discusses the use of platelet-rich plasma (PRP) in regenerative plastic surgery and dermatology for hair regrowth and skin revitalization, noting some potential side effects without reporting new clinical results.

This study found that a standardized PRP application protocol was effective as a coadjuvant therapy in most patients with androgenetic alopecia who did not respond to minoxidil or finasteride, based on improvements in Ebling's scale.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

P-3074 effectively blocks scalp DHT better than oral finasteride.

This study outlines a hair regrowth treatment targeting hair follicle stem cells, 5-alpha reductase pathway, and microinflammation using PDGF and VEGF, but reports no clinical results.

This review discusses recent advances in monophosphate prodrug strategies for HCV drug discovery, aiming to enhance oral absorption and stability, and reports no new clinical results.

This molecular docking study reported that danoprevir, remdesivir, and saridegib exhibit stronger binding affinities to the main protease of SARS-CoV-2 than the control, suggesting their potential as inhibitors of the virus's replication process.

In this study, injectable platelet-rich fibrin (I-PRF) was found to be more effective than platelet-rich plasma (PRP) at improving hair growth outcomes and patient satisfaction for androgenic alopecia.

Prostaglandin helps regenerate hair follicles after radiation damage.

Combining PRP with other treatments can improve hair loss outcomes.

PRP treatment for hair loss shows promise, with 58% of patients satisfied and most noticing improvement within 6 months.

This study found that using 5α-reductase inhibitors during active surveillance for low-risk prostate cancer reduced prostate volume by 23% and was associated with a lower progression rate.

This study found that combining stromal vascular fraction with PRP injections significantly improved hair density and reduced hair loss more effectively than PRP alone in patients with androgenetic alopecia.

In this study, activated PRP injections appeared to promote hair growth in AGA-affected scalp skin transplanted onto mice, compared to non-activated PRP.

Created microspheres show potential for safe and effective use in prostate artery embolization.

This study found that autologous non-activated platelet-rich plasma (A-PRP) was effective and safe for treating androgenetic alopecia, showing long-term improvement in hair density, thickness, and count.

This article discusses the FDA's decision not to approve 5α-reductase inhibitors for prostate cancer prevention, citing an increase in high-grade tumors but no mortality evidence, and reports no new results.

AMP-303 injections can increase hair growth in androgenetic alopecia with minimal side effects.

The project developed and tested a method using plasma rich platelets to treat hair loss.

This study found that combining polybrene and a ROCK inhibitor can effectively expand human keratinocyte stem/progenitor cells carrying a transgene, aiding their use in regenerative medicine.

In this study, both VEPA and ML-Y1 treatment regimens for older patients with non-Hodgkin's lymphoma showed similar response and survival rates, but neither was sufficient, indicating the need for a more effective approach.